EUCTR2012-004411-31-PT进行中（未招募）1 期
ong term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome - MAESTRO-OL: MAcitentan in Eisenmenger Syndrome To RestOre exercise capacity (Open-Label)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 217
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects with ES (including those with Down Syndrome [DS]) having completed the double-blind AC-055-305 / MAESTRO study as scheduled, i.e., who remained in the double-blind study up to Week 16 (whether or not they were still taking study drug at the end of this period).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 15
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Subjects who prematurely discontinue double-blind study drug during the AC-055-305 / MAESTRO study due to:
- •- an adverse event (AE) assessed as related to the use of study drug, or
- •- elevated liver tests (LTs; related or unrelated to study drug)
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if macitentan is safe and tolerable enough to be usedfor treatment of idiopathic pulmonary fibrosis, following the MUSICstudyEUCTR2010-024211-13-ESACTELION Pharmaceuticals Ltd.178
进行中（未招募）
1 期
ong-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndromeMedDRA version: 20.0 Level: LLT Classification code 10058554 Term: Eisenmenger's syndrome System Organ Class: 100000164933Eisenmenger SyndromeEUCTR2012-004411-31-GBActelion Pharmaceuticals Ltd217
进行中（未招募）
1 期
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 13.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024211-13-SEACTELION Pharmaceuticals Ltd.178
进行中（未招募）
1 期
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 14.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024211-13-SIACTELION Pharmaceuticals Ltd.178
进行中（未招募）
不适用
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC studyPatients with Idiopathic Pulmonary FibrosisMedDRA version: 13.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-024211-13-DEACTELION Pharmaceuticals Ltd.178